Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CG, Langford CA, Mueller M, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Gu YZ, Snyder RD, Merkel PA.

Arthritis Rheum. 2011 Dec;63(12):3988-97. doi: 10.1002/art.30615.

PMID:
21953143
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.

Monach PA, Warner RL, Tomasson G, Specks U, Stone JH, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Iklé D, Kallenberg CG, Krischer J, Langford CA, Mueller M, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Johnson KJ, Merkel PA.

Ann Rheum Dis. 2013 Aug;72(8):1342-50. doi: 10.1136/annrheumdis-2012-201981. Epub 2012 Sep 12.

PMID:
22975753
[PubMed - indexed for MEDLINE]
3.

Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.

Pullerits R, Ljevak M, Vikgren J, Bokarewa M.

Scand J Immunol. 2012 Oct;76(4):411-20. doi: 10.1111/j.1365-3083.2012.02747.x.

PMID:
22823472
[PubMed - indexed for MEDLINE]
4.

Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.

Monach PA, Kümpers P, Lukasz A, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Carette S, Ding L, Hoffman GS, Iklé D, Kallenberg CG, Khalidi NA, Langford CA, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Haubitz M, Merkel PA.

PLoS One. 2012;7(1):e30197. doi: 10.1371/journal.pone.0030197. Epub 2012 Jan 18.

PMID:
22279570
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides.

Boehme MW, Schmitt WH, Youinou P, Stremmel WR, Gross WL.

Am J Med. 1996 Oct;101(4):387-94.

PMID:
8873509
[PubMed - indexed for MEDLINE]
6.

Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV).

Schneeweis C, Rafalowicz M, Feist E, Buttgereit F, Rudolph PE, Burmester GR, Egerer K.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1 Suppl 57):62-6.

PMID:
20412705
[PubMed - indexed for MEDLINE]
7.

Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.

Tomasson G, Lavalley M, Tanriverdi K, Finkielman JD, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Stone JH, Freedman JE, Merkel PA; Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.

J Rheumatol. 2011 Jun;38(6):1048-54. doi: 10.3899/jrheum.100735. Epub 2011 Mar 16.

PMID:
21411717
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheum. 2013 Sep;65(9):2441-9. doi: 10.1002/art.38044.

PMID:
23754238
[PubMed - indexed for MEDLINE]
Free Article
9.

Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis.

Wang C, Gou SJ, Chang DY, Yu F, Zhao MH, Chen M.

Arthritis Care Res (Hoboken). 2013 Nov;65(11):1828-34. doi: 10.1002/acr.22187.

PMID:
24591411
[PubMed - indexed for MEDLINE]
10.

Circulating soluble adhesion molecules in ANCA-associated vasculitis.

Ara J, Mirapeix E, Arrizabalaga P, Rodriguez R, Ascaso C, Abellana R, Font J, Darnell A.

Nephrol Dial Transplant. 2001 Feb;16(2):276-85.

PMID:
11158400
[PubMed - indexed for MEDLINE]
Free Article
11.

Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy.

Lorenzen J, Lovric S, Krämer R, Haller H, Haubitz M.

Ann Rheum Dis. 2010 Jun;69(6):1169-71. doi: 10.1136/ard.2009.113621. Epub 2010 Apr 27.

PMID:
20424002
[PubMed - indexed for MEDLINE]
12.

Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.

Wendt M, Gunnarsson I, Bratt J, Bruchfeld A.

Scand J Rheumatol. 2012 Mar;41(2):116-9. doi: 10.3109/03009742.2011.620573. Epub 2011 Nov 28.

PMID:
22118245
[PubMed - indexed for MEDLINE]
13.

High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations.

Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I.

Mol Med. 2011 Jan-Feb;17(1-2):29-35. doi: 10.2119/molmed.2010.00132. Epub 2010 Sep 10.

PMID:
20844833
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR.

Arthritis Rheum. 2009 Jul;60(7):2156-68. doi: 10.1002/art.24637.

PMID:
19565480
[PubMed - indexed for MEDLINE]
Free Article
15.

Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.

Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, Guillevin L; French Vasculitis Study Group.

Rheumatology (Oxford). 2014 Mar;53(3):532-9. doi: 10.1093/rheumatology/ket381. Epub 2013 Nov 26.

PMID:
24282319
[PubMed - indexed for MEDLINE]
16.

Induction treatment of ANCA-associated vasculitis with a single dose of rituximab.

Turner-Stokes T, Sandhu E, Pepper RJ, Stolagiewicz NE, Ashley C, Dinneen D, Howie AJ, Salama AD, Burns A, Little MA.

Rheumatology (Oxford). 2014 Aug;53(8):1395-403. doi: 10.1093/rheumatology/ket489. Epub 2014 Mar 7.

PMID:
24609057
[PubMed - indexed for MEDLINE]
17.

Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis.

Chen M, Wang F, Zhao MH.

Rheumatology (Oxford). 2009 Apr;48(4):355-8. doi: 10.1093/rheumatology/ken500. Epub 2009 Jan 30.

PMID:
19181656
[PubMed - indexed for MEDLINE]
Free Article
18.

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2013 Mar;8(3):382-91. doi: 10.2215/CJN.03950412. Epub 2013 Jan 4.

PMID:
23293123
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Is serum HMGB1 a biomarker in ANCA-associated vasculitis?

de Souza A, Westra J, Bijzet J, Limburg PC, Stegeman CA, Bijl M, Kallenberg CG.

Arthritis Res Ther. 2013;15(5):R104.

PMID:
24007972
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Gou SJ, Yuan J, Chen M, Yu F, Zhao MH.

Kidney Int. 2013 Jan;83(1):129-37. doi: 10.1038/ki.2012.313. Epub 2012 Aug 22.

PMID:
22913983
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk